AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Stellar Biotechnologies, Inc. has been awarded $3 million from the National Cancer Institute of the [U.S.] National Institutes of Health for the development of production methods, quality standards, and facilities for the commercialization of keyhole limpet hemocyanin (KLH) for use in anti-cancer vaccines.
The award is a competing continuation of a Small Business Innovative Research (SBIR) phase 2 grant previously awarded to the company for the development of aquaculture technology for Megathura crenulata (the source animal for KLH) and is funded through the NCI's FLAIR (Flexible System to Advance Innovative Research) program for small businesses.
KLH is a highly immunogenic, T cell-dependent protein used as a vaccine platform or "carrier" molecule for vaccine antigens. By combining KLH with tumor-associated antigens, anti-cancer vaccines are formulated to overcome the immune system's tolerance of "self" antigens, resulting in robust ...
Source: HighBeam Research, Biotech company receives $3 million NCI award for anticancer vaccine...